TL;DR
This study reveals a novel way bacterial IMP dehydrogenases (IMPDHs) bind their essential cofactor, NAD+. This unique binding mode, involving a pocket also targeted by bacterial-specific inhibitors, explains why these inhibitors are effective against bacteria but not humans, offering a promising strategy for developing new antibiotics.
What Problem Does This Paper Address?
The rise of antibiotic-resistant bacteria is a critical global health threat, necessitating the discovery of new antimicrobial agents and drug targets. Inosine 5'-monophosphate dehydrogenase (IMPDH) is a key enzyme in bacterial guanine nucleotide biosynthesis and a promising target for new antibiotics. While potent inhibitors of bacterial IMPDHs have been developed, their selectivity over human IMPDHs was not fully understood. Specifically, these bacterial inhibitors bind to a pocket absent in human IMPDHs, and the role of this pocket, particularly in relation to cofactor binding, remained unclear. This paper aims to elucidate the structural basis for this inhibitor selectivity by examining the binding of both inhibitors and the NAD+ cofactor in various bacterial IMPDHs.
Methods
The researchers employed X-ray crystallography to determine the structures of several bacterial IMPDHs in complex with their substrates, products, inhibitors, and the cofactor NAD+. They specifically focused on IMPDHs from Bacillus anthracis, Campylobacter jejuni, and Clostridium perfringens, which possess a unique structural motif (IMSM) that contributes to inhibitor binding. They also studied Vibrio cholerae IMPDH, which lacks this motif and is resistant to these inhibitors, serving as a control. To facilitate crystallization and structural analysis, they engineered CBS domain deletion variants of these enzymes. Inhibition assays were conducted to quantify the potency of various inhibitors against these bacterial IMPDHs.
Datasets
The study utilized crystal structures of IMPDHs from Bacillus anthracis, Campylobacter jejuni, Clostridium perfringens, and Vibrio cholerae. These structures were determined in complex with IMP, XMP, NAD+, and various inhibitors. The atomic coordinates and structure factors for these complexes have been deposited in the Protein Data Bank (PDB) under accession codes 4X3Z, 4MJM, 4MYA, 4MY1, 4Q32, 4Q33, 4MY9, 4QM1, 4MYX, 4MY8, 4MZ8, 4MZ1, and 4QNE.
Key Insights and Ideas
- A Bacterial-Specific NAD+ Binding Pocket: The most significant finding is the identification of a distinct NAD+ binding mode in bacterial IMPDHs, particularly in the Vibrio cholerae enzyme. This mode differs dramatically from that observed in eukaryotic IMPDHs, with the NAD+ adenosine moiety occupying a pocket that is also utilized by bacterial-specific inhibitors.
- Inhibitors Mimic Cofactor Binding: The bacterial-specific inhibitors, which target a pocket absent in human IMPDHs, appear to "mimic" or occupy a similar space as the NAD+ cofactor's adenosine moiety in this newly identified bacterial binding site. This explains their selectivity.
- Structural Basis for Selectivity: The presence of the "inhibitor minimal structural motif" (IMSM) in many bacterial IMPDHs, composed of specific amino acid residues, is crucial for both inhibitor binding and the novel NAD+ binding mode. The absence of this motif in Vibrio cholerae IMPDH, for instance, correlates with its resistance to these inhibitors.
- Dynamic Active Site Flap: The study highlights the conformational flexibility of the active site flap in bacterial IMPDHs, suggesting its dynamic nature plays a role in accommodating ligands and potentially influencing inhibitor affinity and selectivity.
- Implications for Drug Design: Understanding this unique cofactor-binding pocket and its overlap with inhibitor binding sites provides a rational basis for designing more potent and selective antibacterial agents that specifically target bacterial IMPDHs.
Key Results
The study determined 13 crystal structures, revealing detailed interactions between bacterial IMPDHs and their ligands. Key results include:
- Novel NAD+ Conformation: Structures of Vibrio cholerae IMPDH with IMP/NAD+ and XMP/NAD+ showed NAD+ adopting a more compact conformation than typically seen in dehydrogenases, with its adenosine moiety binding in a "bacterial AB-subsite" located in an adjacent monomer.
- Inhibitor-Targeted Pocket: This bacterial AB-subsite is the same pocket exploited by bacterial-specific IMPDH inhibitors, explaining their selectivity.
- Structure-Activity Relationships: Inhibition assays demonstrated that while many bacterial IMPDHs are sensitive to CpIMPDH-derived inhibitors, Vibrio cholerae IMPDH is resistant, consistent with its lack of the IMSM. Subtle differences in inhibitor binding and protein-inhibitor interactions were observed even among sensitive bacterial IMPDHs, contributing to varying potencies.
- Catalytic Intermediate Captured: A structure of Vibrio cholerae IMPDH with IMP and NAD+ captured a mixture of substrate and the covalent intermediate E-XMP*, providing insights into the dehydrogenase step of the reaction.
Limitations and Future Work
The authors acknowledge that the crystal structures, while providing significant insights, are of medium resolution, which introduces a level of uncertainty in some atomic positions. The active site flap was often disordered, limiting detailed analysis of its role in the hydrolysis step of the catalytic cycle.
Future work could focus on:
- Higher Resolution Structures: Obtaining higher resolution structures, particularly of the active site flap in different conformations, could provide more definitive insights into the catalytic mechanism and ligand interactions.
- Further Inhibitor Optimization: Leveraging the detailed structural information to design and synthesize new inhibitors with enhanced potency and selectivity, potentially by targeting specific interactions within the AB-subsite.
- Exploring Other Bacterial IMPDHs: Investigating the NAD+ binding mode and inhibitor interactions in a broader range of bacterial IMPDHs to understand the evolutionary divergence of this enzyme.
- In Vivo Validation: Testing the efficacy of newly designed inhibitors in preclinical models to confirm their potential as novel antibiotics.
Summary updated